DISSABS / 1999:39502

AN

    1999:39502  DISSABS   Order Number: AAIC701050 (not available for sale by
    UMI)

TI

    EFFECTS ON ENERGY UTILIZATION AND EXPRESSION OF THE OBESITY GENE AND
    UNCOUPLING PROTEINS (UCP1 AND UCP2) BY NEW BETA-3 ADRENERGIC AGONIST IN
    RATS FED A CAFETERIA DIET
    EFECTOS EN LA UTILIZACION ENERGETICA Y EN LA EXPRESION DEL GEN DE LA
    OBESIDAD Y PROTEINAS DESACOPLANTES (UCP1 Y UCP3) DE UN NUEVO AGONISTA
    ADRENERGICO BETA3 EN UN MODELO DE OBESIDAD INDUCIDA CON UNA DIETA DE
    CAFETERIA

AU

    BERRAONDO LOPEZ, BEATRIZ [DR.]

CS

    UNIVERSIDAD DE NAVARRA (SPAIN) (5864)

SO

    Dissertation Abstracts International, (1998) Vol. 60, No. 2C, p. 362.
    Order No.: AAIC701050 (not available for sale by UMI). 286 pages. FACULTY
    OF PHARMACY, UNIVERSITY OF NAVARRA, E-31080 PAMPLONA, SPAIN. 

DT

    Dissertation

FS

    DAI

LA

    Spanish

AB

        The $\beta3$-adrenergic agonists demonstrate major lipolytic,
    thermogenic and hypoglucaemic effects, and are potentially applicable in
    the treatment of obesity and diabetes. In this paper, we study the
    effects on energy consumption and the expression of the obesity gene and
    uncoupling proteins (UCP1 and UCP2) when the new $\beta3$-adrenergic
    agonist, Trecadrine, was administered for 35 days in a model of obesity
    induced by a cafeteria diet in female Wistar rats. Trecadrine (1 mg/kg)
    was given to the obese animals, and was found to reduce significantly
    their body weight and fat deposits as a result of an increase in lipolysis
    in the white and brown fat, as Trecadrine increases the activity of
    hormone-sensitive lipase and the consumption of oxygen in vitro in
    white fat. At the same time, the administration of Trecadrine (1 mg/kg) to
    obese rats produced an increase in thermogenesis, mediated by a rise in
    UCP1 expression in brown fat and UCP2 in the gastrocnemius muscle, the
    principal modulators of which seem to be the fatty acids which are
    mobilized when lipolysis is stimulated. However, UCP2 expression in the
    gastrocnemius was reduced in control rats treated with Trecadrine (1
    mg/kg), which suggests that the response was different in control animals
    from that in obese ones. Similarly, the administration of Trecadrine (1
    mg/kg) to obese animals brought down the plasma leptin levels and the
    amount of obesity gene which was expressed. In conclusion, Trecadrine
    could be of great interest for the treatment of obesity.

CC

    0570 HEALTH SCIENCES, NUTRITION; 0307 BIOLOGY, MOLECULAR; 0433 BIOLOGY,
    ANIMAL PHYSIOLOGY